Sustained Intraocular Pressure Rise after the Treat and Extend Regimen at 3 Years: Aflibercept versus Ranibizumab

Table 1

Univariate and multivariate analysis of characteristics associated with IOP spikes after antivascular endothelial growth factor agents in the treat and extend regimen.

Characteristics	Univariate analysis			Multivariate analysis
	Odds ratio	95% CI	value	Adjusted OR	CI	value
Age (years)
>70	Ref
<70	3.34	1.32–5.72	0.012	3.72	1.72–4.63	0.015
Gender
Female	Ref
Male	2.83	1.02–4.76	0.024	2.94	1.1–4.89	0.018
Lens status
Pseudophakic	Ref
Phakic	1.04	0.84–1.46	0.21
Etiology
DME	Ref
AMD	3.31	1.34–4.28	0.01	2.40	1.43–4.57	0.009
RVO	1.47	1.23–2.12	0.28
Anti-VEGF agent
Aflibercept	Ref
Ranibizumab	6.62	2.95–8.89	0.001	5.85	2.07–7.24	0.001
Ac angle
TM seen	Ref
TM not seen	4.27	3.17–5.94	0.002	3.15	1.87–5.34	0.017
Ethnicity
German	Ref
South Asian	2.89	1.76–5.13	0.023	3.14	1.87–4.32	0.013
Turkish	1.57	1.33–2.19	0.22
Arab	1.42	1.32–1.89	0.19
Short-term IOP rise
No	Ref
Yes	2.31	2.12–4.33	0.24
Baseline IOP
<14 mm Hg	Ref
14 mm or higher	2.17	1.27–5.32	0.12
Ranibizumab volume (ml)
0.03
0.05	4.31	2.18–6.75	0.001	3.78	1.32–5.75	0.001
Treatment interval (weeks)
4	Ref
>4	2.31	2.09–4.12	0.11
Number of injections
3 or less	Ref
3–6	3.35	1.67–3.87	0.07
>6	3.24	2.09–5.08	0.012	4.11	1.83–5.39	0.001
Therapy switch
To aflibercept	Ref
To ranibizumab	4.13	2.29–6.03	0.003	3.78	2.10–4.78	0.002
To DEXI	3.11	2.87–5.4	0.09
To avastin	5.12	2.56–7.25	0.011	4.55	2.17–6.78	0.002
Glaucoma
No glaucoma	Ref
Preexisting	3.11	2.78–5.97	0.013	4.13	3.12–5.89	0.001
F/H glaucoma
No	Ref
Yes	1.57	1.33–4.21	0.14
Axial length (mm)
23.0–25.0	Ref
<23.0	2.34	1.42–5.22	0.13
>25.0	1.85	1.2–3.98	0.10

CI: confidence interval, DME: diabetic macular edema, OR: odds ratio, value, AMD: age-related macular degeneration, RVO: retinal vein occlusion, TM: trabecular meshwork, DEXI: dexamethasone implant. “Ref” is short for “Reference for statistical comparison of independent variables with more than one possible outcome during multivariate analysis.